Anja Harmeier
Directeur Général chez ReWind Therapeutics NV
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Cornelis Kees | M | - |
ReWind Therapeutics NV
ReWind Therapeutics NV Pharmaceuticals: MajorHealth Technology ReWind Therapeutics NV is a biotech company based in Leuven, Belgium that develops first-in-class remyelinating therapies for myelin-related diseases. The Belgian company's aim is to bring these therapies into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged, leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition, and movement, among others. ReWind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. The company's team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics. The company was founded in 2017 by Ku Leuven's Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. The CEO of the company since 2021 is Anja Harmeier. | 4 ans |
Jim van Heusden | M | 53 |
ReWind Therapeutics NV
ReWind Therapeutics NV Pharmaceuticals: MajorHealth Technology ReWind Therapeutics NV is a biotech company based in Leuven, Belgium that develops first-in-class remyelinating therapies for myelin-related diseases. The Belgian company's aim is to bring these therapies into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged, leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition, and movement, among others. ReWind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. The company's team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics. The company was founded in 2017 by Ku Leuven's Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. The CEO of the company since 2021 is Anja Harmeier. | - |
Claus Asbjørn Andersson | M | 56 |
ReWind Therapeutics NV
ReWind Therapeutics NV Pharmaceuticals: MajorHealth Technology ReWind Therapeutics NV is a biotech company based in Leuven, Belgium that develops first-in-class remyelinating therapies for myelin-related diseases. The Belgian company's aim is to bring these therapies into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged, leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition, and movement, among others. ReWind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. The company's team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics. The company was founded in 2017 by Ku Leuven's Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. The CEO of the company since 2021 is Anja Harmeier. | 1 ans |
Olivier Danos | M | 66 |
Corlieve Therapeutics SAS
Corlieve Therapeutics SAS Pharmaceuticals: MajorHealth Technology Corlieve Therapeutics SAS provides neurology services. The company was founded by Richard Porter, Valerie Crepel and Christophe Mulle in November 2019 and is headquartered in Paris, France. | - |
Vanessa Malier | F | 51 |
Corlieve Therapeutics SAS
Corlieve Therapeutics SAS Pharmaceuticals: MajorHealth Technology Corlieve Therapeutics SAS provides neurology services. The company was founded by Richard Porter, Valerie Crepel and Christophe Mulle in November 2019 and is headquartered in Paris, France. | - |
David Evans | M | - |
Roche Ventures
Roche Ventures Investment ManagersFinance Roche Ventures is the venture investment division of the pharmaceutical company F. Hoffmann-La Roche Ltd., which is a subsidiary of Roche Holding AG (SWX:ROG). The group is headquartered in Basel with operations and affiliates worldwide, and is a world leader in pharmaceuticals and diagnostics. The firm was founded in 2002. | 5 ans |
Nicholas Barbet | M | - |
Corlieve Therapeutics SAS
Corlieve Therapeutics SAS Pharmaceuticals: MajorHealth Technology Corlieve Therapeutics SAS provides neurology services. The company was founded by Richard Porter, Valerie Crepel and Christophe Mulle in November 2019 and is headquartered in Paris, France. | - |
Catherine Lubetzki | F | - |
ReWind Therapeutics NV
ReWind Therapeutics NV Pharmaceuticals: MajorHealth Technology ReWind Therapeutics NV is a biotech company based in Leuven, Belgium that develops first-in-class remyelinating therapies for myelin-related diseases. The Belgian company's aim is to bring these therapies into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged, leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition, and movement, among others. ReWind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. The company's team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics. The company was founded in 2017 by Ku Leuven's Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. The CEO of the company since 2021 is Anja Harmeier. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Dominic Schmidt | M | 42 |
Freie Universität Berlin
| 5 ans |
Fabián Jorge Rodríguez Simón | M | 65 |
Instituto de Empresa SL
| 8 ans |
Carlos Sahuquillo | M | - |
Instituto de Empresa SL
| 4 ans |
Juan Pablo Miro | M | - |
Instituto de Empresa SL
| 2 ans |
Valeria Domínguez González | F | - |
Instituto de Empresa SL
| 2 ans |
Maria Santis | F | - |
Instituto de Empresa SL
| 4 ans |
Jordan Thurlow | M | - |
Instituto de Empresa SL
| 2 ans |
Martina Nan Chen | F | - |
Instituto de Empresa SL
| - |
Sergio Choclan Gómez | M | - |
Instituto de Empresa SL
| 1 ans |
Karteek Pulapaka | M | - |
Instituto de Empresa SL
| 1 ans |
Riad Nourallah | M | 43 |
Freie Universität Berlin
| 4 ans |
Christopher Calicott | M | - |
Instituto de Empresa SL
| 1 ans |
Beatriz Fernández | M | - |
Instituto de Empresa SL
| 1 ans |
Kerstin Lopatta | M | 55 |
Freie Universität Berlin
| 4 ans |
Jan Lubke | M | - |
Instituto de Empresa SL
| 4 ans |
Arnd Lodowicks | M | - |
Freie Universität Berlin
| 5 ans |
Mathias Thorsheim | M | - |
Instituto de Empresa SL
| 4 ans |
Felix Hagemeier | M | - |
Instituto de Empresa SL
| 1 ans |
Jack Pederzoli | M | - |
Instituto de Empresa SL
| 4 ans |
Damiano Coletti | M | - |
Instituto de Empresa SL
| 1 ans |
Olivier Nantois | M | - |
Instituto de Empresa SL
| 1 ans |
Christine C. | F | - |
Instituto de Empresa SL
| 1 ans |
David Galindo | M | - |
Instituto de Empresa SL
| 1 ans |
Kimian Guetzkow | M | - |
Instituto de Empresa SL
| 4 ans |
Mauricio Weiss | M | - |
Instituto de Empresa SL
| 1 ans |
Sherif Mahmoud Ahmed | M | 44 |
Instituto de Empresa SL
| 1 ans |
Antonio Negro | M | - |
Instituto de Empresa SL
| 2 ans |
Nigel Jacob | M | - |
Instituto de Empresa SL
| 1 ans |
Maciej Andrzej Libiszewski | M | 51 |
Freie Universität Berlin
| - |
Íñigo Rezola de Vargas | M | - |
Instituto de Empresa SL
| - |
Agnes L. Blanco Querido | F | 43 |
Instituto de Empresa SL
| 1 ans |
Yehia Abouelwafa | M | - |
Instituto de Empresa SL
| 1 ans |
José Luis Jiménez Guajardo-Fajardo | M | 56 |
Instituto de Empresa SL
| 18 ans |
Monique Schiersing | M | - |
Roche Ventures
Roche Ventures Investment ManagersFinance Roche Ventures is the venture investment division of the pharmaceutical company F. Hoffmann-La Roche Ltd., which is a subsidiary of Roche Holding AG (SWX:ROG). The group is headquartered in Basel with operations and affiliates worldwide, and is a world leader in pharmaceuticals and diagnostics. The firm was founded in 2002. | 9 ans |
Konrad Schäfers | M | 37 |
Freie Universität Berlin
| 4 ans |
Ian J. Reynolds | M | - |
ReWind Therapeutics NV
ReWind Therapeutics NV Pharmaceuticals: MajorHealth Technology ReWind Therapeutics NV is a biotech company based in Leuven, Belgium that develops first-in-class remyelinating therapies for myelin-related diseases. The Belgian company's aim is to bring these therapies into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged, leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition, and movement, among others. ReWind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. The company's team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics. The company was founded in 2017 by Ku Leuven's Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. The CEO of the company since 2021 is Anja Harmeier. | 3 ans |
Fabian Süßenguth | M | - |
Instituto de Empresa SL
| - |
Jorge Felix Schnura Becerro | M | - |
Instituto de Empresa SL
| 6 ans |
Martina Weiner | F | - |
Freie Universität Berlin
| 4 ans |
Maksim Vladimirovich Pustovoy | M | 48 |
Instituto de Empresa SL
| 2 ans |
Marija Stipic | F | - |
Freie Universität Berlin
| 4 ans |
Benedikt Woelki | M | 46 |
Freie Universität Berlin
| 7 ans |
Ben Cousens | M | - |
Instituto de Empresa SL
| 1 ans |
Mwanyisa Tendai | M | - |
Instituto de Empresa SL
| 1 ans |
Tareq Khalid Hamad Al-Angari | M | - |
Instituto de Empresa SL
| 1 ans |
Analore García | F | - |
Instituto de Empresa SL
| 4 ans |
Adrien Tamagno | M | - |
Instituto de Empresa SL
| 1 ans |
Joffrey Ezerzer | M | - |
Instituto de Empresa SL
| 1 ans |
Varun Loyalka | M | 33 |
Instituto de Empresa SL
| 2 ans |
João Lopes Raimundo | M | - |
Instituto de Empresa SL
| 4 ans |
Sonia Yosef | F | - |
Instituto de Empresa SL
| - |
Anshul Agarwala | M | - |
Instituto de Empresa SL
| 1 ans |
Federica Loguercio | F | - |
Instituto de Empresa SL
| 1 ans |
Lucia Lacalle | F | - |
Instituto de Empresa SL
| 1 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Espagne | 43 | 69,35% |
Allemagne | 9 | 14,52% |
Belgique | 5 | 8,06% |
France | 3 | 4,84% |
Suisse | 2 | 3,23% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Anja Harmeier
- Réseau Personnel